908 Devices (NASDAQ:MASS – Get Free Report) and Anteris Technologies Global (NASDAQ:AVR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.
Analyst Ratings
This is a breakdown of current recommendations for 908 Devices and Anteris Technologies Global, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 908 Devices | 1 | 0 | 1 | 0 | 2.00 |
| Anteris Technologies Global | 1 | 0 | 4 | 0 | 2.60 |
908 Devices presently has a consensus target price of $12.00, indicating a potential upside of 36.46%. Anteris Technologies Global has a consensus target price of $16.00, indicating a potential upside of 65.56%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, analysts plainly believe Anteris Technologies Global is more favorable than 908 Devices.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| 908 Devices | -62.40% | -14.03% | -10.40% |
| Anteris Technologies Global | -5,148.78% | -124.76% | -101.21% |
Risk and Volatility
908 Devices has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.
Earnings and Valuation
This table compares 908 Devices and Anteris Technologies Global”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 908 Devices | $57.80 million | 5.75 | $19.49 million | ($1.00) | -8.79 |
| Anteris Technologies Global | $1.91 million | 492.51 | -$94.14 million | ($2.23) | -4.33 |
908 Devices has higher revenue and earnings than Anteris Technologies Global. 908 Devices is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
88.1% of 908 Devices shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
908 Devices beats Anteris Technologies Global on 8 of the 14 factors compared between the two stocks.
About 908 Devices
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.
